Royal London Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.03M | Sell |
3,919
-301
| -7% | -$230K | 0.01% | 562 |
|
|
2025
Q4 | $3.26M | Sell |
4,220
-287
| -6% | -$195K | 0.01% | 556 |
|
|
2025
Q3 | $2.53M | Sell |
4,507
-42,064
| -90% | -$23.8M | 0.01% | 564 |
|
|
2025
Q2 | $24.4M | Sell |
46,571
-3,061
| -6% | -$1.71M | 0.06% | 273 |
|
|
2025
Q1 | $31.5M | Buy |
49,632
+5,548
| +13% | +$3.82M | 0.07% | 234 |
|
|
2024
Q4 | $31.4M | Buy |
44,084
+409
| +0.9% | +$343K | 0.08% | 216 |
|
|
2024
Q3 | $45.9M | Buy |
43,675
+1,152
| +3% | +$1.28M | 0.11% | 159 |
|
|
2024
Q2 | $44.7M | Buy |
42,523
+1,463
| +4% | +$1.42M | 0.11% | 151 |
|
|
2024
Q1 | $39.5M | Sell |
41,060
-589
| -1% | -$560K | 0.1% | 172 |
|
|
2023
Q4 | $36.6M | Buy |
41,649
+1,068
| +3% | +$879K | 0.1% | 168 |
|
|
2023
Q3 | $33.4M | Buy |
40,581
+1,652
| +4% | +$1.3M | 0.11% | 164 |
|
|
2023
Q2 | $28M | Buy |
38,929
+2,231
| +6% | +$1.72M | 0.09% | 183 |
|
|
2023
Q1 | $30.2M | Sell |
36,698
-149
| -0.4% | -$112K | 0.12% | 142 |
|
|
2022
Q4 | $26.6M | Buy |
36,847
+1,824
| +5% | +$1.35M | 0.12% | 156 |
|
|
2022
Q3 | $24.1M | Sell |
35,023
-1,305
| -4% | -$821K | 0.12% | 150 |
|
|
2022
Q2 | $21.5M | Buy |
36,328
+316
| +0.9% | +$205K | 0.1% | 173 |
|
|
2022
Q1 | $25.2M | Buy |
36,012
+1,830
| +5% | +$1.16M | 0.1% | 175 |
|
|
2021
Q4 | $21.6M | Sell |
34,182
-602
| -2% | -$370K | 0.08% | 202 |
|
|
2021
Q3 | $21M | Buy |
34,784
+512
| +1% | +$318K | 0.09% | 196 |
|
|
2021
Q2 | $19.1M | Sell |
34,272
-1,858
| -5% | -$941K | 0.08% | 212 |
|
|
2021
Q1 | $17.1M | Buy |
36,130
+990
| +3% | +$482K | 0.08% | 215 |
|
|
2020
Q4 | $17M | Sell |
35,140
-2,271
| -6% | -$1.23M | 0.09% | 199 |
|
|
2020
Q3 | $21.5M | Sell |
37,411
-32
| -0.1% | -$19.4K | 0.13% | 144 |
|
|
2020
Q2 | $22.9M | Buy |
37,443
+5,722
| +18% | +$3.25M | 0.16% | 127 |
|
|
2020
Q1 | $15M | Sell |
31,721
-143
| -0.4% | -$59K | 0.12% | 176 |
|
|
2019
Q4 | $11.9M | Sell |
31,864
-231
| -0.7% | -$77.7K | 0.08% | 233 |
|
|
2019
Q3 | $8.9M | Buy |
32,095
+210
| +0.7% | +$62.1K | 0.07% | 284 |
|
|
2019
Q2 | $9.98M | Sell |
31,885
-389
| -1% | -$130K | 0.09% | 218 |
|
|
2019
Q1 | $13.3M | Sell |
32,274
-1,724
| -5% | -$710K | 0.1% | 207 |
|
|
2018
Q4 | $12.3M | Buy |
33,998
+1,857
| +6% | +$680K | 0.11% | 202 |
|
|
2018
Q3 | $13M | Sell |
32,141
-1,499
| -4% | -$570K | 0.13% | 161 |
|
|
2018
Q2 | $11.6M | Buy |
+33,640
| New | +$10.5M | 0.12% | 188 |
|
|
2016
Q2 | $9.61M | Sell |
27,509
-7,067,884
| -100% | -$2.72B | 0.16% | 139 |
|
|
2016
Q1 | $20K | Buy |
7,095,393
+7,066,511
| +24,467% | +$2.91B | 0.03% | 467 |
|
|
2015
Q4 | $15.8M | Buy |
28,882
+402
| +1% | +$218K | 0.24% | 97 |
|
|
2015
Q3 | $13.2M | Buy |
+28,480
| New | +$15.3M | 0.21% | 111 |
|
|
2014
Q4 | $101K | Buy |
24,653
+5,701
| +30% | +$2.24M | 0.19% | 125 |
|
|
2014
Q3 | $6.73M | Buy |
18,952
+1,000
| +6% | +$335K | 0.17% | 136 |
|
|
2014
Q2 | $6.12M | Sell |
17,952
-79
| -0.4% | -$23.4K | 0.14% | 165 |
|
|
2014
Q1 | $5.25M | Sell |
18,031
-216
| -1% | -$66.5K | 0.12% | 188 |
|
|
2013
Q4 | $5.01M | Buy |
18,247
+876
| +5% | +$252K | 0.13% | 184 |
|
|
2013
Q3 | $5.29M | Buy |
17,371
+395
| +2% | +$104K | 0.14% | 170 |
|
|
2013
Q2 | $3.98M | Buy |
+16,976
| New | +$3.95M | 0.12% | 199 |
|
Other funds holding REGN
VCM
N
Royal London Asset Management's REGN Position: Q1 2026 in Review
Royal London Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 7.1% in Q1 2026, selling an estimated $230K and leaving 3,919 shares worth $3.03M. The position accounts for 0.01% of the portfolio, ranked #562.
Royal London Asset Management first reported a position in REGN in Q2 2013 and has held it in 43 quarters since. The position peaked at $45.9M in Q3 2024. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Royal London Asset Management held 3,919 shares of Regeneron Pharmaceuticals worth $3.03M as of Q1 2026.
- Royal London Asset Management sold 301 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $230K.
- Regeneron Pharmaceuticals made up 0.01% of Royal London Asset Management's portfolio in Q1 2026, its #562 holding.
- Royal London Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Royal London Asset Management's Regeneron Pharmaceuticals position peaked at $45.9M in Q3 2024.
- 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Royal London Asset Management's 13F filing for Q1 2026, filed 1 May 2026.